+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

  • PDF Icon

    Report

  • 93 Pages
  • May 2023
  • Region: Global
  • GlobalData
  • ID: 5823110
The publisher's Medical Devices sector report, 'Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update' provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Diabetes Assays comprises of C-Peptide Assay, Glycated Hemoglobin (HbA1c) Lab Assay, Glycated Hemoglobin (HbA1c) Point of care (POC) Assay, Insulin Assay and Fasting Glucose Assay.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Diabetes Assays under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Diabetes Assays under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes Assays Overview
3 Products under Development
3.1 Diabetes Assays - Pipeline Products by Stage of Development
3.2 Diabetes Assays - Pipeline Products by Segment
3.3 Diabetes Assays - Pipeline Products by Territory
3.4 Diabetes Assays - Pipeline Products by Regulatory Path
3.5 Diabetes Assays - Pipeline Products by Estimated Approval Date
4 Diabetes Assays - Pipeline Products under Development by Companies
4.1 Diabetes Assays Companies - Pipeline Products by Stage of Development
4.2 Diabetes Assays - Pipeline Products by Stage of Development
5 Diabetes Assays Companies and Product Overview6 Diabetes Assays- Recent Developments
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Segment
  • Diabetes Assays - Pipeline Products by Territory
  • Diabetes Assays - Pipeline Products by Regulatory Path
  • Diabetes Assays - Pipeline Products by Estimated Approval Date
  • Diabetes Assays Companies - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Glossary
List of Figures
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Segment
  • Diabetes Assays - Pipeline Products by Territory
  • Diabetes Assays - Pipeline Products by Regulatory Path
  • Diabetes Assays - Pipeline Products by Estimated Approval Date
  • Diabetes Assays - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abcodia Ltd
  • Adaptive Biotechnologies Corp
  • Adipomics Inc
  • Aditxt Inc
  • Alfa Wassermann Inc
  • AmideBio, LLC
  • Aura Biotechnologies Pvt Ltd
  • Beckman Coulter Inc
  • Biocrates Life Sciences AG
  • BioDesign Institute at Arizona State University
  • CellCarta Precision Medicine Inc
  • Confer Health Inc
  • Drexel University
  • ELITechGroup Inc
  • Enable Biosciences Inc
  • FibroStatin SL
  • G Medical Innovations Holdings Ltd
  • GATC DB Care Corp
  • Gelteq Pty Ltd
  • Genesis Detection Systems, Inc.
  • Guangzhou Wondfo Biotech Co Ltd
  • Helmholtz Centre for Infection Research
  • Hemex Health Inc
  • Human Cell Design SAS
  • IntraMed Diagnostics, LLC
  • Janssen Diagnostics LLC
  • Johns Hopkins University
  • L2 Diagnostics LLC
  • Matter Diagnostics
  • MediSure Canada Inc
  • Mellitus LLC
  • Numares AG
  • Peri Rx Inc
  • PortaScience Inc
  • Precision Diabetes LLC
  • Protagen AG
  • Queen Mary University of London
  • QuickCheck Health Inc
  • Sebia SA
  • Sera Prognostics Inc
  • Singulex Inc
  • SomaLogic Inc
  • The Forsyth Institute
  • University of Canterbury
  • University of Colorado
  • University of Florida
  • University of Newcastle
  • University of Oxford
  • University of South Florida
  • University of Strathclyde
  • Vactech Oy
  • Wave 80 Biosciences Inc
  • Xhale Inc
  • Yaathum Biotech Pvt Ltd